AC Immune SA
NASDAQ:ACIU
AC Immune SA
Revenue
AC Immune SA
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
AC Immune SA
NASDAQ:ACIU
|
Revenue
CHf14.8m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Revenue
$69.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
129%
|
CAGR 10-Years
N/A
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Revenue
$371.2m
|
CAGR 3-Years
709%
|
CAGR 5-Years
160%
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Revenue
CHf157.6m
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
14%
|
|
Idorsia Ltd
SIX:IDIA
|
Revenue
CHf97.1m
|
CAGR 3-Years
60%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Kuros Biosciences AG
SIX:KURN
|
Revenue
CHf33.6m
|
CAGR 3-Years
103%
|
CAGR 5-Years
116%
|
CAGR 10-Years
N/A
|
See Also
What is AC Immune SA's Revenue?
Revenue
14.8m
CHF
Based on the financial report for Dec 31, 2023, AC Immune SA's Revenue amounts to 14.8m CHF.
What is AC Immune SA's Revenue growth rate?
Revenue CAGR 5Y
16%
Over the last year, the Revenue growth was 280%. The average annual Revenue growth rates for AC Immune SA have been -1% over the past three years , 16% over the past five years .